LIVERFASt Simplifies Liver Assessment for Clinicians

The future of healthcare begins long before treatment—it starts with accurate diagnostics, reliable laboratory testing, and scientific innovation. The Association for Diagnostics & Laboratory Medicine (ADLM) brings together a global community of laboratory professionals, researchers, clinicians, healthcare leaders, and technology innovators committed to transforming patient care through better diagnostics. #ADLM #ClinicalDiagnostics #LaboratoryMedicine #HealthcareInnovation #Diagnostics #HealthcareTechnology #LifeSciences #PrecisionMedicine #MedicalLaboratory #ClinicalLaboratory #Biotechnology #Pathology #DigitalHealth #HealthcareTransformation #PatientCare #MedTech #ScientificInnovation #FutureOfHealthcare

The future of healthcare will not be defined by how we treat disease, but by how early and accurately we detect it. Advances in clinical testing are transforming healthcare through precision diagnostics, AI assisted analysis, molecular testing, and earlier disease detection. These innovations are helping clinicians make more informed decisions while improving patient outcomes. At Bharat Biosense, we believe every breakthrough in diagnostics brings us one step closer to more personalized, preventive, and effective healthcare. Because better testing doesn't just deliver results. It delivers better decisions. What advancement in clinical diagnostics do you believe will have the greatest impact on healthcare over the next decade? #ClinicalTesting #PrecisionDiagnostics #HealthcareInnovation #MedicalTechnology #Diagnostics #Biotechnology #PrecisionMedicine #DigitalHealth #LifeSciences #FutureOfHealthcare

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗥𝗮𝗻𝗱𝗼𝗺-𝗔𝗰𝗰𝗲𝘀𝘀 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗮𝘁 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲 At 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲, Atila BioSystems is excited to introduce a new generation of 𝗿𝗮𝗻𝗱𝗼𝗺-𝗮𝗰𝗰𝗲𝘀𝘀 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀—combining affordability, portability, automation, and fast turnaround times in a single platform. This Point of Care molecular test platform allows you to run multiple different assays simultaneously, improve turnaround times, and maximize patient management efficiency while maintaining exceptional accuracy and reliability. Our innovative solution enables laboratories, physicians, and healthcare clinics to: 🔹 Process samples immediately as they arrive 🔹 Run multiple different molecular assays simultaneously 🔹 Deliver results in under 60 minutes 🔹 Improve workflow efficiency and patient management 🔹 Expand access to high-quality molecular diagnostics 📍 𝗩𝗶𝘀𝗶𝘁 𝗔𝘁𝗶𝗹𝗮 𝗕𝗶𝗼𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗮𝘁 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟬𝟲𝟱 📅 𝗔𝗗𝗟𝗠 𝟮𝟬𝟮𝟲 | 𝗝𝘂𝗹𝘆 𝟮𝟲–𝟯𝟬 | 𝗔𝗻𝗮𝗵𝗲𝗶𝗺, 𝗖𝗮𝗹𝗶𝗳𝗼𝗿𝗻𝗶𝗮 Stop by our booth to see the platform in action and learn how Atila BioSystems is making molecular diagnostics more accessible, efficient, and affordable. #ADLM2026 #MolecularDiagnostics #PointOfCare #Diagnostics #PCR #MolecularTesting #HealthcareInnovation #AtilaBioSystems #RandomAccess

Navigating the field of Clinical and Translational OMICS is challenging, but it is also one of the most promising frontiers in modern healthcare. The true value of OMICS is not simply generating molecular information, it's translating that information into meaningful clinical decisions that improve patient outcomes. Across every medical specialty, Clinical and Translational OMICS has the potential to transform healthcare by enabling earlier prevention, more accurate diagnosis, and more personalized treatment. It bridges the gap between molecular discoveries and real-world patient care, empowering clinicians to make informed decisions tailored to each individual. As technology continues to advance, our greatest opportunity lies not only in discovering new biomarkers, but in integrating molecular insights with clinical expertise to deliver tangible benefits for patients and their families. The future of medicine is collaborative, patient-centered, and driven by the successful translation of scientific discoveries into everyday clinical practice. #ClinicalOmics #TranslationalMedicine #PrecisionMedicine #GenomicMedicine #MolecularMedicine #PersonalizedMedicine #ClinicalGenomics #HealthcareInnovation #PatientCare

𝗠𝗮𝘀𝘁𝗲𝗿 𝗣𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀: 𝗔 𝗦𝗺𝗮𝗿𝘁𝗲𝗿 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗠𝗼𝗱𝗲𝗿𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 Traditional clinical trials often evaluate one treatment for one disease at a time. 𝗠𝗮𝘀𝘁𝗲𝗿 𝗣𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 are transforming this approach by allowing multiple therapies, patient groups, or research questions to be studied under a single overarching protocol. By using a shared infrastructure, master protocols improve efficiency, reduce costs, and accelerate the development of new treatments without compromising scientific rigor. 𝗪𝗵𝘆 𝗠𝗮𝘀𝘁𝗲𝗿 𝗣𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 𝗠𝗮𝘁𝘁𝗲𝗿 ✔ Faster evaluation of multiple therapies ✔ More efficient patient recruitment and resource utilization ✔ Greater flexibility to add or remove treatment arms ✔ Reduced operational complexity and timelines ✔ Accelerated delivery of innovative treatments to patients As precision medicine continues to evolve, 𝗠𝗮𝘀𝘁𝗲𝗿 𝗣𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 are becoming a cornerstone of innovative, patient-centric clinical research—helping researchers generate high-quality evidence while bringing life-changing therapies to patients faster. 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝘀𝗻'𝘁 𝗷𝘂𝘀𝘁 𝗮𝗯𝗼𝘂𝘁 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝗻𝗲𝘄 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀—𝗶𝘁'𝘀 𝗮𝗯𝗼𝘂𝘁 𝗱𝗲𝘀𝗶𝗴𝗻𝗶𝗻𝗴 𝘀𝗺𝗮𝗿𝘁𝗲𝗿 𝘁𝗿𝗶𝗮𝗹𝘀 𝘁𝗵𝗮𝘁 𝗱𝗲𝗹𝗶𝘃𝗲𝗿 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁𝗹𝘆. 𝗩𝗶𝘀𝗶𝘁: www.galaxbiotech.xn--com-4p60bpa 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 𝗮𝘁 𝗴𝗮𝗹𝗮𝘅@𝗴𝗮𝗹𝗮𝘅𝗯𝗶𝗼𝘁𝗲𝗰𝗵.𝗰𝗼𝗺 𝗼𝗿 𝗰𝗮𝗹𝗹 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝗼𝗻 +𝟵𝟭 𝟵𝟴𝟳𝟲𝟱𝟰𝟰𝟭𝟳𝟰. #𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 #𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗧𝗿𝗶𝗮𝗹𝘀 #𝗠𝗮𝘀𝘁𝗲𝗿𝗣𝗿𝗼𝘁𝗼𝗰𝗼𝗹𝘀 #𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 #𝗗𝗿𝘂𝗴𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 #𝗟𝗶𝗳𝗲𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 #𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 #𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 #𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 #𝗙𝘂𝘁𝘂𝗿𝗲𝗢𝗳𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵

Rare diseases require a different approach to innovation. When patients have limited time and treatment options, traditional clinical trial models aren't always enough. In his latest episode of the Med Tech Gurus podcast, Excelerant Consulting, LLC Partner Thomas Hickey sits down with Dr. Rob Freishtat to discuss how adaptive clinical trial designs, personalized medicine, mRNA therapies, and patient-centered research are transforming the future of rare disease treatment. With nearly 350 episodes, Med Tech Gurus continues to bring healthcare and medical device professionals conversations with industry leaders who are driving meaningful change. Listen to the latest episode below, and be sure to follow the podcast for new episodes each week.

Time is Lives! The Med Tech Gurus Perspective by Thomas Hickey This week's episode of Med Tech Gurus features Dr. Rob Freishtat, MD, MPH—physician, scientist, former President and Co-Founder of Uncommon Cures, and a recognized leader in rare disease clinical development and personalized medicine. Dr. Freishtat has spent his career challenging one of healthcare's biggest assumptions: What if the clinical trial—not the science—is what's slowing innovation? In our conversation, he explains why adaptive trial design, smarter collaboration, and patient-centered development are changing how therapies reach people living with rare diseases. Dr. Freishtat also makes a compelling case that commercialization should begin long before FDA approval. One statement from Rob has stayed with me: "Time isn't money. Time is lives." My Perspective I've been fortunate to interview hundreds of MedTech innovators, and one theme keeps emerging. The biggest breakthroughs rarely come from better technology alone. They come from people willing to challenge the way we've always done things. That's exactly what Dr. Freishtat and so many leaders in rare disease are doing. They're not just developing new therapies. They're redesigning the path that gets those therapies to patients. If you're a founder, investor, clinician, or anyone involved in MedTech or Biotech innovation, I think you'll find this conversation well worth your time. #MedTech #Biotech #RareDisease #ClinicalTrials #PrecisionMedicine #HealthcareInnovation #PersonalizedMedicine #DrugDevelopment #MedicalDevices #HealthTech

A milestone worth marking at IDMEDICO: our first data collection phase with transfusion-dependent thalassemia patients is complete. 46 patients. Over 800,000 raw PPG samples, captured alongside routine clinical care and now processed end to end through our analysis pipeline. Thalassemia is a deliberate starting point. Patients receive regular transfusions, hemoglobin follows a predictable pattern between visits, and routine pre-transfusion blood counts provide dense reference data. If continuous non-invasive monitoring is going to be useful anywhere, this is where it should prove itself first. The image below is from our signal conditioning work raw wrist PPG on the left, the same trace after processing on the right. Getting this step right matters more than most people expect; a lot of what looks like sensor noise turns out to be a processing question. The pipeline is built, the data is in, and analysis is underway. Findings will be reported properly in a forthcoming paper rather than in fragments here. My thanks to the clinical teams who made this possible, and above all to the patients who agreed to take part in something that offers them no immediate benefit. #DigitalHealth #Thalassemia #RemotePatientMonitoring #HealthTech

Explore our NEW #CLL Sessions feature 🎥 💬 🩸 With experts: 🎙️ Othman Al-Sawaf 🎙️ Lydia Scarfò 🎙️ Alessandra Tedeschi They explore key advances and clinical decision-making in #chroniclymphocyticleukemia (#CLL), focusing on: 📌 The choice between continuous #BTKinhibitor treatment and fixed-duration #venetoclax-based regimens 📌 How #biomarkers such as #TP53 status and patient characteristics guide treatment decisions, and summarize findings from the CLL17 trial (NCT04608318) 📌 They also address challenges in treatment sequencing and relapse management, commenting on emerging strategies, including #MRD-guided therapy and novel combination regimens, as key areas for future optimization Take a look 👉 https://lnkd.in/e6aA2yMR

Patient engagement is not only a part of the treatment but also determines its success.   It's the mindset and the strategy.💡   This pharmaphorum article by Amy Bucher, Ph.D., FSBM of Lirio explores why meaningful patient engagement drives improved health outcomes and commercial success. It also highlights that behavioral science, patient-centricity, and AI work better together than in isolation.   👉 Discover how understanding patient needs and motivations can create value for both healthcare and pharma, and learn more via MyMA: 🔗 https://lnkd.in/gD-H7zM7 Read the article and tell us: what is meaningful patient engagement for you? 🩺   #MedicalAffairs #PatientEngagement #PatientCentricity #Pharma #Healthcare